Can test-mix gains become durable diagnostic economics?
- Occurrence
- Unresolved
- Record state
- Active
- Lock date
- August 7, 2026
- Original measurement date
- October 15, 2026
- Next measurement date
- November 15, 2026
- Evidence date
- Not published
The Nkengbeza Ledger
Loading research note…
Retrieving the published evidence and analysis.
GeneDx has demonstrated stronger scale, exome/genome mix, and reported gross margin.
Thesis outcome tracking
These published occurrence records are linked to this exact thesis. A locked occurrence question does not establish a numerical Expected Impact, realized impact, or Catalyst Outcome Grade.
A comparison is published only after the thesis reaches its stated evidence and measurement gates.
Occurrence is neutral. It records whether the catalyst happened and does not determine the company consequence.
The forward-locked company-direction expectation is preserved before realized evidence opens.
Measures the attributable company-direction consequence from operating and commercial evidence, not share-price performance.
Measures breadth and demonstrated company reach. Grade depth is excluded, and unresolved evidence remains off-scale.
A nested comparison is published only when both periods contain the same persistent catalyst set.